Claims for Patent: 10,420,838

Summary for Patent: 10,420,838

Title:	Methods for treating cancer using iNOS-inhibitory compositions
Abstract:	Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human melanoma, or a head or neck cancer, that employ therapeutically-effective amounts of one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents (including, for example, calcium channel antagonists), alone, or further in combination with one or more conventional chemotherapeutic agents. Also disclosed are pharmaceutical formulations that comprise these compositions, as well as methods for their use in treating refractory, metastatic, and/or relapsed cancers, or, for use in the management or reversal of treatment resistance in one or more such mammalian cancers.
Inventor(s):	Chang; Jenny Chee Ning (Houston, TX)
Assignee:	The Methodist Hospital (Houston, TX)
Application Number:	15/486,183
Patent Claims:	1. A method of treating or ameliorating one or more symptoms of melanoma or a head/neck cancer in an animal in need thereof, the method comprising administering to the animal (a) a composition comprising: 1) a therapeutically-effective amount of N.sup.G-monomethyl-L-arginine [L-NMMA]; 2) a therapeutically-effective amount of amlodipine; and 3) a therapeutically-effective amount of a first chemotherapeutic agent; for a time sufficient to treat or ameliorate the one or more symptoms of melanoma or the head/neck cancer in the animal. 2. The method of claim 1, wherein the melanoma or the head/neck cancer is identified as a refractory or a relapsed form of the disease. 3. The method of claim 1, wherein the melanoma or the head/neck cancer is characterized as treatment-resistant, radioresistant, metastatic, or any combination thereof. 4. The method of claim 1, wherein the composition further comprises: 4) one or more of an immunomodulating agent, a neuroactive agent, an anti-inflammatory agent, an anti-lipidemic agent, a hormone, a receptor agonist, a receptor antagonist, an anti-infective agent, a protein, a peptide, an antibody, an antigen-binding fragment of an antibody, an enzyme, an RNA, a DNA, an siRNA, an mRNA, a ribozyme, a hormone, a cofactor, a steroid, an antisense molecule, a second distinct antihypertensive agent, a second distinct chemotherapeutic agent, or any combination thereof. 5. The method of claim 4, wherein the antibody is selected from the group consisting of an anti-CDI antibody, an anti-PD1 antibody, an anti-PD-L1 antibody, and any combination thereof. 6. The method of claim 4, wherein the antigen-binding fragment is obtained from an anti-CDI antibody, an anti-PD1 antibody, an anti-PD-L1 antibody, or any combination thereof, or wherein the antigen-binding fragment comprises at least one antigenically-active fragment of one or more of said antibodies. 7. The method of claim 1, wherein the first chemotherapeutic agent comprises: one or more antineoplastic compounds, one or more cytotoxic compounds, one or more cytostatic compounds, one or more cytoreductive compounds, or any combination thereof. 8. The method of claim 1, wherein the first chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, 5-fluorouracil, docetaxel, paclitaxel, trastuzumab, methotrexate, epirubicin, cis-platin, carboplatin, vinorelbine, capecitabine, gemcitabine, mitoxantrone, isabepilone, eribulin, lapatinib, carmustine, a nitrogen mustard, a sulfur mustard, a platin tetranitrate, vinblastine, etoposide, camptothecin, and any combination thereof. 9. The method of claim 8, wherein the first chemotherapeutic agent is docetaxel. 10. The method of claim 1, wherein the composition further comprises a pharmaceutically-acceptable carrier, buffer, diluent, vehicle, excipient, or any combination thereof. 11. The method of claim 1, wherein the composition is formulated for systemic administration to a human. 12. The method of claim 11, wherein the composition is provided to the human in a series of consecutive systemic doses administered over a period of several days to several weeks. 13. The method of claim 1, further comprising administering to the animal: (b) one or more chemotherapeutically-effective doses of radiation. 14. A method of treating or ameliorating one or more symptoms of melanoma in a mammal, comprising: systemically administering to the mammal a composition that comprises: therapeutically-effective amounts of: a) N.sup.G-monomethyl-L-arginine [L-NMMA]; b) amlodipine; and docetaxel; for a time sufficient to treat or ameliorate the one or more symptoms of melanoma in the mammal. 15. The method of claim 14, further comprising the additional step of administering to the body of the animal one or more chemotherapeutically-effective doses of ionizing radiation. 16. A method of treating or ameliorating one or more symptoms of a head/neck cancer in a mammal, comprising: systemically administering to the mammal a composition that comprises: therapeutically-effective amounts of: a) N.sup.G-monomethyl-L-arginine [L-NMMA]; b) amlodipine; and docetaxel; for a time sufficient to treat or ameliorate the one or more symptoms of the head/neck cancer in the mammal. 17. The method of claim 16, further comprising the additional step of administering to the body of the animal one or more chemotherapeutically-effective doses of ionizing radiation. 18. A method of treating or ameliorating one or more symptoms of melanoma or a head/neck cancer in a mammal in need thereof, the method comprising administering to the animal: (a) a composition comprising: 1) a therapeutically-effective amount of N.sup.G-monomethyl-L-arginine (L-NMMA); 2) a therapeutically-effective amount of amlodipine; and 3) a chemotherapeutically-effective amount of docetaxel, for a time sufficient to treat or ameliorate the one or more symptoms of melanoma or the head/neck cancer in the mammal. 19. The method of claim 18, further comprising administering to the mammal: (b) a therapeutically-effective amount of pembrolizumab. 20. The method of claim 19, wherein the therapeutically-effective amount of pembrolizumab administered to the mammal is about 10 mg/kg per day. 21. The method of claim 18, wherein the therapeutically-effective amount of L-NMMA administered to the mammal is about 80 mg/kg to about 400 mg/kg per day. 22. The method of claim 18, wherein the therapeutically-effective amount of docetaxel administered to the mammal is about 20 mg/kg per day. 23. The method of claim 18, wherein the therapeutically-effective amount of amlodipine administered to the mammal is about 10 mg/kg per day. 24. The method of claim 1, wherein the therapeutically-effective amount of L-NMMA is about 80 mg/kg to about 400 mg/kg per day, and the therapeutically-effective amount of amlodipine is about 10 mg/kg per day.

Details for Patent 10,420,838

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-04-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-04-08
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2034-04-08
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2034-04-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2034-04-08